Buy New

or
Sign in to turn on 1-Click ordering.
or
Amazon Prime Free Trial required. Sign up when you check out. Learn More
Buy Used
Used - Good See details
$16.26 & eligible for FREE Super Saver Shipping on orders over $25. Details

or
Sign in to turn on 1-Click ordering.
 
   
Sell Back Your Copy
For a $4.69 Gift Card
Trade in
More Buying Choices
Have one to sell? Sell yours here
Biocapital: The Constitution of Postgenomic Life
 
 
Tell the Publisher!
I'd like to read this book on Kindle

Don't have a Kindle? Get your Kindle here, or download a FREE Kindle Reading App.

Biocapital: The Constitution of Postgenomic Life [Paperback]

Kaushik Sunder Rajan (Author)
4.8 out of 5 stars  See all reviews (4 customer reviews)

List Price: $25.95
Price: $19.13 & eligible for FREE Super Saver Shipping on orders over $25. Details
You Save: $6.82 (26%)
  Special Offers Available
o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o
In Stock.
Ships from and sold by Amazon.com. Gift-wrap available.
Only 16 left in stock--order soon (more on the way).
Want it delivered Tuesday, January 31? Choose One-Day Shipping at checkout. Details
Textbook Student FREE Two-Day Shipping for Students. Learn more

Formats

Amazon Price New from Used from
Hardcover $75.92  
Paperback $19.13  
Sell Back Your Copy for $4.69
Whether you buy it used on Amazon for $12.95 or somewhere else, you can sell it back through our Book Trade-In Program at the current price of $4.69.
Used Price$12.95
Trade-in Price$4.69
Price after
Trade-in
$8.26

Book Description

0822337207 978-0822337201 April 24, 2006
Biocapital is a major theoretical contribution to science studies and political economy. Grounding his analysis in a multi-sited ethnography of genomic research and drug development marketplaces in the United States and India, Kaushik Sunder Rajan argues that contemporary biotechnologies such as genomics can only be understood in relation to the economic markets within which they emerge. Sunder Rajan conducted fieldwork in biotechnology labs and in small start-up companies in the United States (mostly in the San Francisco Bay area) and India (mainly in New Delhi, Hyderabad, and Bombay) over a five-year period spanning 1999 to 2004. He draws on his research with scientists, entrepreneurs, venture capitalists, and policymakers to compare drug development in the two countries, examining the practices and goals of research, the financing mechanisms, the relevant government regulations, and the hype and marketing surrounding promising new technologies. In the process, he illuminates the global flow of ideas, information, capital, and people connected to biotech initiatives.

Sunder Rajan’s ethnography informs his theoretically sophisticated inquiry into how the contemporary world is shaped by the marriage of biotechnology and market forces, by what he calls technoscientific capitalism. Bringing Marxian theories of value into conversation with Foucaultian notions of biopolitics, he traces how the life sciences came to be significant producers of both economic and epistemic value in the late twentieth century and early twenty-first.


Special Offers and Product Promotions

  • Buy $50 in qualifying physical textbooks, get $5 in Amazon MP3 Credit. Here's how (restrictions apply)

Frequently Bought Together

Biocapital: The Constitution of Postgenomic Life + Life As Surplus: Biotechnology and Capitalism in the Neoliberal Era + The Politics of Life Itself: Biomedicine, Power, and Subjectivity in the Twenty-First Century (In-Formation)
Price For All Three: $55.67

Some of these items ship sooner than the others. Show details

Buy the selected items together


Editorial Reviews

Review

Biocapital is an ambitious book; its conceptual scope has the potential to remake conversation in the human sciences. There is really nothing like the argument and synthesis Kaushik Sunder Rajan provides, which is surprising given how important his topic is.”—Lawrence Cohen, author of No Aging in India: Alzheimer’s, the Bad Family, and Other Modern Things


Biocapital is excellent. It offers new insight into both late capitalism and the life sciences and also provides material and arguments for rethinking foundational concepts such as ‘valuation’ and ‘exchange.’”—Kim Fortun, author of Advocacy after Bhopal: Environmentalism, Disaster, New Global Orders


“Reading Kaushik Sunder Rajan’s Biocapital fills me with the same intellectual and personal excitement I felt reading Marx’s Capital and Foucault’s History of Sexuality for the first time. Biocapital gives a passionate, thoroughly argued road map to dense and consequential worlds that I already inhabit, but have not known how to describe with the vividness and acumen required. Sunder Rajan integrates and explores in depth what many others only promise; i.e., the coproductions of meanings, values, and bodies in emerging regimes of biocapital. In the course of shaping ethnographic and theoretical inquiry into what he calls ‘lively capital,’ Sunder Rajan gives his readers lively value in every sense.”—Donna Haraway, author of Modest_Witness@Second_Millennium.FemaleMan©_Meets_OncoMouse™

From the Publisher

"Reading Kaushik Sunder Rajan’s Biocapital fills me with the same intellectual and personal excitement I felt reading Marx’s Capital and Foucault’s History of Sexuality for the first time. Biocapital gives a passionate, thoroughly argued road map to dense and consequential worlds that I already inhabit, but have not known how to describe with the vividness and acumen required. Sunder Rajan integrates and explores in depth what many others only promise; i.e., the coproductions of meanings, values, and bodies in emerging regimes of biocapital. In the course of shaping ethnographic and theoretical inquiry into what he calls ‘lively capital,’ Sunder Rajan gives his readers lively value in every sense."—Donna Haraway, author of Modest_Witness@Second_Millennium.FemaleMan©_Meets_OncoMouse™

"Biocapital is an ambitious book; its conceptual scope has the potential to remake conversation in the human sciences. There is really nothing like the argument and synthesis Kaushik Sunder Rajan provides, which is surprising given how important his topic is."—Lawrence Cohen, author of No Aging in India: Alzheimer’s, the Bad Family, and Other Modern Things

"Biocapital is excellent. It offers new insight into both late capitalism and the life sciences and also provides material and arguments for rethinking foundational concepts such as ‘valuation’ and ‘exchange.’"—Kim Fortun, author of Advocacy after Bhopal: Environmentalism, Disaster, New Global Orders --This text refers to the Hardcover edition.


Product Details

  • Paperback: 360 pages
  • Publisher: Duke University Press Books (April 24, 2006)
  • Language: English
  • ISBN-10: 0822337207
  • ISBN-13: 978-0822337201
  • Product Dimensions: 8.8 x 6.1 x 1 inches
  • Shipping Weight: 3.2 ounces (View shipping rates and policies)
  • Average Customer Review: 4.8 out of 5 stars  See all reviews (4 customer reviews)
  • Amazon Best Sellers Rank: #595,861 in Books (See Top 100 in Books)

More About the Author

Discover books, learn about writers, read author blogs, and more.

 

Customer Reviews

4 Reviews
5 star:
 (3)
4 star:
 (1)
3 star:    (0)
2 star:    (0)
1 star:    (0)
 
 
 
 
 
Average Customer Review
4.8 out of 5 stars (4 customer reviews)
 
 
 
 
Share your thoughts with other customers:
Most Helpful Customer Reviews

7 of 7 people found the following review helpful:
5.0 out of 5 stars Insight into our many possible futures, July 27, 2007
By 
Amazon Verified Purchase(What's this?)
This review is from: Biocapital: The Constitution of Postgenomic Life (Paperback)
"Biocapital" by Kaushik Sunder Rajan is an impressive book that offers a sophisticated analysis of the biotech industry. Written as an MIT graduate student well-grounded in Marxian economics and Foucauldian social theories, Mr. Rajan's ethnographic study compares and contrasts biotech companies in the U.S. and India to illuminate how industrial practices are shaped by a myriad of economic and cultural forces. Among the many insights produced in this fascinating study, the author convincingly demonstrates how the so-called 'life sciences' are representative of a new phase of capitalism that is characterized by the temporality of our postmodern time.

Mr. Rajan discusses how biotech is changing relationships and practices between public and private entities. He explains that high tech capitalism is dependent upon information in order to innovate and produce; traditionally, this service was fulfilled by publicly-funded research institutions. But the speed at which the biotech industry competes has blurred these boundaries; the race to map and "own" the human genome that pitted the National Institute of Health against Celera Genomics is a case in point. The author explores struggles over privacy and ownership rights, finding that governments are responding to these pressures by behaving more like corporations. For example, the U.S. has seen an explosion in partnerships between universities and private corporations while the Indian state has sought to retain genetic property rights for its public hospitals. In this sense, Mr. Rajan's narrative positions the biotech industry squarely in the vanguard of contemporary global economic and institutional change.

Mr. Rajan's extensive comparative analysis reveals how such dynamics play out in markedly different ways in local contexts. In the U.S., the author describes how messianic corporate leaders hype their miracle drugs as salvationary promise; venture capital sometimes finances ritualistic displays of excess that intends to inscribe corporate brands on the minds of investors and employees. The author explains that a reverence for free market capitalism and the fetish of personalized medicine compels investors to risk massive amounts of money on little more than the promise of scientific discovery. However, the process of calling the future into the present creates a tension between the promise and the reality, a problem that is addressed by corporate public relations departments -- including marketing campaigns that are aimed at introducing remedies for consumer patients-in-waiting at progressively earlier stages of intervention.

In India, Mr. Rajan traces technocapitalism to the postcolonial drive to invest in science as a path to empowering the independent state. Consequently, he finds that Indian entrepreneurship is much more conservative than in the U.S. In fact, many Indian companies tend to engage in production or research work on a contractual basis for western businesses. The author discusses how the ideal of the American free market is often balanced against socialist values that stress the sharing of scientific discovery to the benefit of the community, suggesting how struggles over the future of the Indian economy might be waged.

Interestingly, Mr. Rajan chose GeneEd as the major case study for the book in part because it highlights the experiences of Indian entrepreneurs working and living in the U.S. The fascinating narrative reveals how the hegemonic power of capitalism instills social meaning among workers who dedicate themselves to fulfilling the firm's mission. Yet the author finds age-old themes at play, such as the alienation of labor that resulted from the company's pursuit of a growth strategy that commodified some skill sets while valuing others. Despite the fact that GeneEd plays a peripheral industry role, the structural and cultural logics of biotech become visible to us thanks to Mr. Rajan's brilliantly perceptive and expert commentary. We learn how GeneEd might have evolved but was moved in a particular direction owing to a mix of external market forces and the specific decisions of its capable leadership team.

I highly recommend this book to demanding readers interested in an interdisciplinary perspective on technoscientific capitalism and its connection to our past, the present, and our many possible futures.
Help other customers find the most helpful reviews 
Was this review helpful to you? Yes No


6 of 7 people found the following review helpful:
4.0 out of 5 stars Updating Marx's meisterwork for the 21st century, January 21, 2007
By 
Sunil Maulik (San Francisco, CA) - See all my reviews
(REAL NAME)   
This review is from: Biocapital: The Constitution of Postgenomic Life (Paperback)
Sunder Rajan expertly disassembles and reconstitutes the rapidly growing global industry behind "life sciences" - showing that life itself has become a new form of capital, or biocapital. In contrast to labor, wealth or materials, biocapital realizes its value through explicit ownership of the intellectual property locked away within living things. Sunder Rajan convincingly demonstrates, by situating himself in both American and Indian "life science" companies, that the ultimate ownership, transfer and wealth-creation that intellectual property (IP) provides does not always fall to the expected recepients.

(Full disclosure. I and my company are featured extensively in one chapter of this book.)
Help other customers find the most helpful reviews 
Was this review helpful to you? Yes No


0 of 1 people found the following review helpful:
5.0 out of 5 stars Wow. Indeed., February 2, 2011
Amazon Verified Purchase(What's this?)
This review is from: Biocapital: The Constitution of Postgenomic Life (Paperback)
Thank you for writing the book. As someone who is engaged in a similar process, it gives me hope and serves as an inspiration.
Help other customers find the most helpful reviews 
Was this review helpful to you? Yes No

Share your thoughts with other customers: Create your own review
 
 
 
Most Recent Customer Reviews


Only search this product's reviews



Inside This Book (learn more)
Key Phrases - Statistically Improbable Phrases (SIPs): (learn more)
drug development marketplace, promissory horizon, consumer genomics, drug development enterprise, surplus value generation, new corporate activism, genome companies, working draft sequence, venture science, market terrains, genome company, personalized medicine, multisited ethnography, speculative capitalism, big pharmaceutical companies, genomics companies, risk discourse, therapeutic molecule, venture capital money, market logic, public researchers, patient advocacy groups
Key Phrases - Capitalized Phrases (CAPs): (learn more)
United States, Silicon Valley, Andhra Pradesh, Randy Scott, Third World, Genomic Health, San Francisco, Wall Street, Craig Venter, East Coast, Human Genome Project, Chandrababu Naidu, Joseph Dumit, Celera Genomics, Patrick Terry, Sunil Maulik, Astra Zeneca, Barry Werth, Donna Haraway, Genome Center, Genome Valley, Health Sector Database, Incyte Genomics, Industrial Revolution, Millennium Pharmaceuticals
New!
Books on Related Topics | Concordance | Text Stats
Browse Sample Pages:
Front Cover | Table of Contents | First Pages | Index | Surprise Me!
Search Inside This Book:





Tags Customers Associate with This Product

 (What's this?)
Click on a tag to find related items, discussions, and people.
 
(1)

Your tags: Add your first tag
 

Sell a Digital Version of This Book in the Kindle Store

If you are a publisher or author and hold the digital rights to a book, you can sell a digital version of it in our Kindle Store. Learn more

Customer Discussions

This product's forum
Discussion Replies Latest Post
No discussions yet

Ask questions, Share opinions, Gain insight
Start a new discussion
Topic:
First post:
Prompts for sign-in
 


Active discussions in related forums
Search Customer Discussions
Search all Amazon discussions
   
Related forums



So You'd Like to...



Look for Similar Items by Category


Look for Similar Items by Subject